INmune Bio received a combined approximately $6.4M in research and development refunds from both Australia and the United Kingdom. The Company will use the rebates to reinvest in its clinical programs, particularly the ongoing Phase 2 Alzheimer’s Disease trial in Australia and Canada.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on INMB:
- INmune Bio, Inc. Receives Approximately $6.4 Million in Research and Development Rebates from Australia and the United Kingdom
- INmune Bio, Inc. Announces Pre-Clinical Data That Support a Pioneering Approach to Treating Duchenne Muscular Dystrophy
- INmune Bio announces pre-clinical data on treatment approach for DMD
- INmune Bio , VCU, Barrow Neurological receive DoD funding
- INmune Bio, Inc., Virginia Commonwealth University, and Barrow Neurological Institute Receive Department of Defense Funding to Study the Role of Traumatic Brain Injury in the Development of Alzheimer’s Disease
